Intuitive Surgical — Apr 22, 2025 release

“As we look ahead, we remain focused on enabling our customers to deliver on their goals: better patient outcomes, improved patient and care team experiences, lower total cost to treat, and increased access to care.” 2025 Financial Outlook The Company expects the following results for the full year of 2025: • Worldwide da Vinci procedure growth of approximately 15% to 17% in 2025, compared to 17% in 2024. • Non-GAAP* gross profit margin to be within a range of 65% and 66.5% of revenue in 2025, compared to 69.1% in 2024. This range includes an estimated impact from tariffs of 1.7% of revenue, plus or minus 30 basis points. • Non-GAAP* operating expense growth of 10% to 14% in 2025, compared to 10% in 2024. The updated range for expected non-GAAP* gross profit margin reflects the Company’s estimates of the impact from tariffs that are in effect or have been announced with both a firm percentage and implementation date as of the time of this press release and assumes such tariffs remain in place. Should additional tariffs be implemented, the adverse impact on the Company’s financial results in 2025 (including the decrease in expected non-GAAP* gross profit margin) could be material. The ultimate impact from any tariffs will depend on various factors, including the volume of system sales in China, the proportion of components procured and finished goods manufactured outside of the United States, and the amount, scope, nature, and timing of the tariffs. The 2025 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimat